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Background: OX40 is a member of the tumor necrosis factor receptor family that is expressed primarily on
activated CD4+ T cells and promotes the development of effector and memory T cells. Although OX40 has been
reported to be a target gene of human T-cell leukemia virus type-1 (HTLV-1) viral transactivator Tax and is
overexpressed in vivo in adult T-cell leukemia (ATL) cells, an association between OX40 and HTLV-1-associated
inflammatory disorders, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), has not yet
been established. Moreover, because abrogation of OX40 signals ameliorates chronic inflammation in animal
models of autoimmune disease, novel monoclonal antibodies against OX40 may offer a potential treatment for
HTLV-1-associated diseases such as ATL and HAM/TSP.
Results: In this study, we showed that OX40 was specifically expressed in CD4+ T cells naturally infected with HTLV-1
that have the potential to produce pro-inflammatory cytokines along with Tax expression. We also showed that OX40
was overexpressed in spinal cord infiltrating mononuclear cells in a clinically progressive HAM/TSP patient with a short
duration of illness. The levels of the soluble form of OX40 (sOX40) in the cerebrospinal fluid (CSF) from chronic
progressive HAM/TSP patients or from patients with other inflammatory neurological diseases (OINDs) were not
different. In contrast, sOX40 levels in the CSF of rapidly progressing HAM/TSP patients were higher than those in the
CSF from patients with OINDs, and these patients showed higher sOX40 levels in the CSF than in the plasma. When
our newly produced monoclonal antibody against OX40 was added to peripheral blood mononuclear cells in culture,
HTLV-1-infected T cells were specifically removed by a mechanism that depends on antibody-dependent cellular
cytotoxicity.
Conclusions: Our study identified OX40 as a key molecule and biomarker for rapid progression of HAM/TSP.
Furthermore, blocking OX40 may have potential in therapeutic intervention for HAM/TSP.
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Human T-cell leukemia virus type 1 (HTLV-1) was the
first human oncogenic retrovirus to be identified and
associated with distinct human diseases such as adult
T-cell leukemia (ATL) [1,2] and HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP)
[3,4]. HAM/TSP is a chronic progressive myelopathy
characterized by spastic paraparesis, sphincter dysfunc-
tion, and mild sensory disturbance in the lower extrem-
ities [5]. In addition to neurological symptoms, some
HAM/TSP patients also exhibit autoimmune-like disor-
ders such as uveitis, arthritis, T-lymphocyte alveolitis,
polymyositis, and Sjögren syndrome [6]. Major patho-
logical features of HAM/TSP are chronic inflammation of
the spinal cord, characterized by perivascular lymphocytic
cuffing and parenchymal lymphocytic infiltration that
includes HTLV-1-infected CD4+ T cells [7]. In HAM/TSP
patients, the median HTLV-1 proviral load (PVL), which
reflects the in vivo number of HTLV-1-infected lympho-
cytes, is more than 10 times higher than that in asymp-
tomatic carriers (ACs) [8]. An increase in PVL typically
coincides with worsening of clinical symptoms [9]. In-
creased concentrations of inflammatory markers such as
neopterin [10], tumor necrosis factor (TNF)-α, interleukin
(IL)-6, and interferon (IFN)-γ [11], and increase in HTLV-
1 antigen-specific intrathecal antibody synthesis [12] have
been observed in the cerebrospinal fluid (CSF) of HAM/
TSP patients. More recently, it has been reported that
IFN-stimulated genes were overexpressed in circulating
leukocytes and the expression correlated with the clinical
severity of HAM/TSP [13]. These findings indicate that a
pro-inflammatory environment, associated with increased
numbers of HTLV-1-infected cells, is a characteristic im-
munologic profile of HAM/TSP.
OX40, also known as CD134 or TNFRSF4, is a member
of the TNF co-stimulatory receptor family and is expressed
on activated T cells [14]. OX40 is specifically up-regulated
by the HTLV-1 viral transactivator Tax [15,16]. The ligand
of OX40 (OX40L), which belongs to the TNF superfamily,
was first identified as glycoprotein 34 (gp34) on HTLV-
1-transformed cells [17], and it was later found to bind
OX40 [18]. OX40-OX40L interactions alter the activity
and differentiation of many kinds of immune cells, includ-
ing regulatory T cells (Tregs), T cells, antigen-presenting
cells (APCs), natural killer (NK) cells, and natural killer T
(NKT) cells [14]. Previous studies have reported that OX40
is constitutively expressed in ATL cells and participate in
cell adhesion [19]. Specifically, OX40 and OX40L directly
mediate the adhesion of activated normal CD4+ T cells, as
well as HTLV-1-transformed T cells, to vascular endothe-
lial cells [20]. Immunohistochemical staining of skin biopsy
specimens from ATL patients also showed constitutive
expression of OX40, suggesting its role in leukemic cell
infiltration, in addition to in vivo cell adhesion [19].Recent research has also shown the importance of
OX40-OX40L interactions in the development of immune-
mediated diseases. In particular, a strong reduction in dis-
ease severity or a complete lack of disease has been
reported when OX40 or OX40L is absent or neutralized in
animal models of multiple sclerosis (MS) [21], allergic
asthma [22], colitis [23], diabetes [24], arthritis [25], athero-
sclerosis [26], graft versus host disease [27], and allograft
rejection [28]. Although HTLV-1 causes an aggressive T
cell malignancy (i.e., ATL) and chronic inflammatory dis-
eases such as HAM/TSP, an association of OX40 with the
inflammatory diseases observed in HTLV-1-infected indi-
viduals has not yet been established.
In this study, we investigated the expression of OX40 in
HAM/TSP patients and found that the increased expres-
sion of OX40 is associated with the rapidly progressive
disease. We also used an in-house monoclonal antibody
(mAb) against human OX40 to test the potential of OX40
as a target molecule for immunotherapy.
Results
Tax-dependent constitutive expression of OX40 in
HTLV-1-infected T cells
OX40 and OX40L have been reported to be overexpressed
in HTLV-1-infected human T-cells lines [15,19,20]. These
findings were obtained using northern blot or western blot
analysis using whole cells; hence, our first aim was to con-
firm and extend these findings at the single-cell level using
flow cytometry. Therefore, we used mAbs against human
OX40 (clone B-7B5) and human OX40L (clone 5A8) pro-
duced in our laboratory. We analyzed six HTLV-1-infected
human T-cell lines (HUT-102, MT-1, MT-2, MT-4, SLB-1,
and C5/MJ). C5/MJ, SLB-1, and MT-4 cells have not been
previously tested for OX40/OX40L expression. As shown
in Figure 1A, expression levels were different in each cell
line: OX40 was overexpressed on the surface of the Tax
positive (Tax+) T-cell lines (HUT-102, MT-2, MT-4, SLB-1,
and C5/MJ), but OX40 was not expressed on the surface of
the Tax negative (Tax-) MT-1 cell line or the uninfected
T cell line (CEM-OX40L). Consistent with previous
studies, these findings suggested that OX40 expression
is Tax dependent. In contrast, OX40L was not always
expressed on the surface of HTLV-1-infected human T-cell
lines or on the uninfected T cell line (CEM-OX40), irre-
spective of Tax expression (Figure 1B).
Next, we confirmed whether OX40 and OX40L protein
expression on the cell surface is induced by Tax at the
single-cell level by flow cytometry. We used JPX-9 cells
[29], a Jurkat (HTLV-1 negative human T cell leukemia
cell line) subclone generated by stable transfection of a
functional Tax expression-plasmid vector, and induced
Tax expression by adding CdCl2 into the culture medium
(final concentration: 10 μM). As shown in Figure 1C,
treatment of JPX-9 cells with CdCl2 induced expression of
Figure 1 (See legend on next page.)
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Figure 1 Tax-dependent constitutive expression of OX40 in HTLV-1-infected T-cell lines and Tax-inducible JPX-9 cell line.
A. Representative histograms of OX40 expression in 6 HTLV-1 infected T-cell lines (HUT-102, MT-1, MT-2, MT-4, C5/MJ, SLB-1) and two
HTLV-1-uninfected T-cell lines (CEM-OX40L and CEM-OX40). Shaded histograms represent the isotype control. Tax+ or Tax- means whether these
cells express Tax (Tax+) or not (Tax-). B. Representative histograms of OX40L expression in 6 HTLV-1 infected T-cell lines (HUT-102, MT-1, MT-2,
MT-4, C5/MJ, SLB-1) and two HTLV-1-uninfected T-cell lines (CEM-OX40L and CEM-OX40). Shaded histograms are isotype controls. C. Flow
cytometric analysis of expression of OX40 after induction of Tax in JPX-9 cells. D. Flow cytometric analysis of expression of OX40L after induction
of Tax in JPX-9 cells. E. Soluble OX40 and OX40L levels in cell culture supernatant and cell lysate from 6 HTLV-1 infected T-cell lines (HUT-102,
MT-1, MT-2, MT-4, C5/MJ, SLB-1) and three HTLV-1-uninfected T-cell lines (CEM-mock, CEM-OX40L and CEM-OX40). F. Soluble OX40 and OX40L
levels in cell culture supernatant and cell lysate from JPX-9 cell line treated with CdCl2 along with the induction of viral transactivator Tax.
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expressed Tax. In contrast, OX40L was not expressed in
JPX-9 cells even after 96 hours post Tax-induction
(Figure 1D).
Previous reports indicated that the soluble forms of
OX40 (sOX40) and OX40L (sOX40L) were detectable in
serum of patients with autoimmune disease and cancer
[30,31]. We therefore examined whether sOX40 and
sOX40L levels were elevated in culture supernatants
from HTLV-1 infected T-cell lines and JPX-9 cells before
and after induction of Tax. In agreement with our flow
cytometry data (Figure 1A), sOX40 was detected in both
culture supernatants and cell lysates of Tax positive C5/
MJ, HUT102, MT-2, MT-4, and SLB-1 cells (Figure 1E,
gray bar). However, sOX40L was not detected in culture
supernatants of any of the samples tested, but it was
readily detectable in cell lysates of Tax positive C5/MJ,
MT-2, MT-4 and SLB1 cells (Figure 1E, light gray bar).
We next examined whether soluble OX40 and OX40L
are induced by Tax in JPX-9 cells. Addition of CdCl2 to
the culture medium of JPX-9 cells resulted in a con-
comitant increase in sOX40 expression within 24 hours,
indicating a strong correlation and functional link be-
tween Tax and sOX40 expression (Figure 1F, left panel).
Interestingly, although OX40L was already present be-
fore induction of Tax, OX40L expression was increased
after 24 hours but was never released into the culture
supernatant as sOX40L within 120 hours after induction
of Tax (Figure 1F, right panel).
Functional OX40 is specifically expressed on the surface
of T cells naturally infected with HTLV-1 that have the
potential to produce pro-inflammatory cytokines
Next, we tested whether OX40 or OX40L expression is
also activated in naturally infected T cells isolated dir-
ectly from HTLV-1-infected individuals. PBMCs were
collected from three non-infected controls (NCs), three
ACs, and four HAM/TSP patients. PBMCs were isolated
from blood samples and harvested directly, or after a 16-
hour in vitro cultivation in the absence of any growth
factors or mitogens. After harvesting, cell samples were
fixed and processed for concomitant detection of Tax,
OX40, or OX40L, and CD4 expression by flow cytome-
try. Similar to the findings for JPX-9 cells, OX40 wasdetected with an anti-OX40 mAb (clones B-7B5) after
16 hours of in vitro cultivation (Figure 2A), but OX40L
was not detected in cultured PBMCs from a HAM/TSP
patient (HAM/TSP1) (Figure 2B). Figure 2C shows that
the Tax protein was detected in CD4+ T cells after culti-
vation. Similar to the JPX-9 cell experiments, OX40 was
expressed almost exclusively in the naturally infected
CD4+ T cells that also expressed Tax (Figure 2D). Similar
findings were observed in all samples tested, irrespective of
disease status (i.e., HAM/TSP or ACs) (Additional file 1:
Figure S1 and Additional file 2: Table S1). The cells from
NCs did not express either OX40 or Tax in CD4+ T cells,
before or after cultivation (data not shown). Real time RT-
PCR also showed that mRNA expression of HTLV-1 tax
and OX40 in CD4+ T cells was increased after cultivation,
both in HAM/TSP patients and ACs (Figure 2E).
It has recently been reported [32], that the expression
of another co-stimulatory member of the TNFR family,
4-1BB, is also up-regulated ex vivo in CD4+ T cells from
HTLV-1-infected individuals, and it was found to be cor-
related with Tax expression (Additional file 1: Figure
S2A and B). However, the expression of OX40 is more
specific for Tax+CD4+ cells than 4-1BB (Figure 2D and
Additional file 1: Figure S2C).
Next, we sought to determine if OX40, expressed on the
surface of Tax+CD4+ T cells from HTLV-1-infected indi-
viduals, is functional. We incubated aliquots of Fc-blocked
PBMCs with biotinylated recombinant soluble OX40L at a
concentration of 2.5 mg/ml for 30 min on ice. Cells were
then fixed and processed for concomitant detection of Tax,
CD4, and PE-streptavidin by flow cytometry. As shown in
Additional file 1: Figure S3, the frequency of CD4+ T cells
that were positively stained with biotinylated recombinant
soluble OX40L and PE-streptavidin was similar to the per-
centage of CD4+ T cells stained by anti-OX40 mAb, indi-
cating that these cells expressed functional OX40.
We further analyzed if CD4+OX40+ T cells in HAM/
TSP patients were capable of producing the inflamma-
tory and neurotoxic cytokines, IFN-γ and TNF-α, which,
according to the bystander damage hypothesis, could
cause central nervous system (CNS) inflammation and
demyelination seen in HAM/TSP patients [33,34]. The
frequency of pro-inflammatory cytokine positive cells
within the OX40+CD4+ and Tax+CD4+ populations from
Figure 2 (See legend on next page.)
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Figure 2 OX40 is specifically expressed on the surface of T cells naturally infected with HTLV-1 that have the potential to produce pro-
inflammatory cytokines. A. OX40 was detected on CD4+ T cells of HAM/TSP patient with anti-OX40 mAb (clones B-7B5) after 16 hours in vitro
cultivation in the absence of any growth factors or mitogen. B. OX40L was not detected on CD4+ T cells of HAM/TSP patient with anti-OX40L
mAb (clones 5A8) after 16 hours in vitro cultivation in the absence of any growth factors or mitogen. C. Tax protein was detected in CD4+ T cells
of HAM/TSP patient after 16 hours in vitro cultivation. D. OX40 was expressed almost exclusively in naturally infected CD4+ T cells that also
expressed Tax in HAM/TSP patient. E. Both HTLV-1 tax and OX40 mRNA expression in CD4+ T cells was increased after 16 hours in vitro
cultivation. F. The frequency of pro-inflammatory cytokine positive cells within the OX40+CD4+ and Tax+CD4+ populations from HTLV-1 infected
individuals are significantly higher than OX40-CD4+ and Tax-CD4+ T cells, respectively (p<0.001, Student’s t- test). One representative experiment

























































































Figure 3 Increased expression of OX40 in vivo in rapidly progressive HAM/TSP patients. A. The plasma levels of soluble OX40 (sOX40)
measured by ELISA. The plasma levels of sOX40 in typical HAM/TSP patients (chronic HAM: n=20), asymptomatic carriers (ACs: n=9) and normal
uninfected healthy controls (NCs: n=13). B. No correlation between the plasma levels of sOX40 and HTLV-1 proviral load (tax copies/
10,000PBMCs) from 29 HTLV-1 infected individuals (20 chronic HAM/TSP patients and 9 ACs). Data were analyzed by Spearman rank correlation.
C. The cerebrospinal fluid (CSF) levels of sOX40 in rapidly progressive HAM/TSP patients (n=3), chronic HAM/TSP patients (n=22) and other
neurological diseases including multiple sclerosis (MS) (n=12), aseptic meningitis (n=8), systemic lupus erythematosus (SLE) with neurological
manifestations (n=5), chronic inflammatory demyelinating polyneuropathy (CIDP) (n=9), Guillain-Barré syndrome (GBS) (n=6), and amyotrophic
lateral sclerosis (ALS) (n=9). Chronic HAM/TSP means typical cases fulfilling diagnostic criteria and rapidly progressive HAM/TSP is defined by
patients’ incapacity to walk unaided within three months after symptoms’ onset. D. The levels of sOX40 in the CSF from HTLV-1 infected other
inflammatory neurological diseases (HTLV-1+ OINDs), i.e. any inflammatory neurological disorders except for HAM/TSP which occurred in HTLV-1
infected individuals, was not significantly different from that of chronic HAM/TSP, whereas the levels of sOX40 from HTLV-1+ OINDs was
significantly increased than that of non-infected OINDs (HTLV-1- OINDs). HTLV-1+ OINDs: 1 multiple sclerosis (MS), 1 SLE with neurological
manifestations, 4 aseptic meningitis. HTLV-1- OINDs: 9 MS, 5 SLE with neurological manifestations, 7 CIDP, 5 GBS.
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CD4+ and Tax-CD4+ T cells, respectively (p < 0.001,
Student's t- test) (Figure 2F and Table 1).
Increased expression of OX40 in vivo in rapidly
progressive HAM/TSP patients
To investigate if OX40 expression is associated with
in vivo pathogenesis of HAM/TSP, we first measured the
plasma concentration of sOX40 and sOX40L in 20
chronic HAM/TSP patients, 9 ACs, and 13 NCs by
ELISA by using monoclonal antibodies generated in our
laboratory (Figure 3A). None of the samples had detect-
able levels of sOX40L (data not shown), but we could
readily detect sOX40. The median level of sOX40 in
NCs was 149.5 pg/ml (range 13–328 pg/ml). Significantly
higher sOX40 levels were found in chronic HAM/TSP pa-
tients (median 395.2 pg/ml, range 113–1295 pg/ml) and
ACs (median 423.8 pg/ml, range 201–881 pg/ml) than in
NCs (p=0.0043 for differences between HAM/TSP and
NCs, p=0.0020 for differences between ACs and NCs).
The difference between chronic HAM/TSP patients and
ACs was not statistically significant. No positive correl-
ation was found between sOX40 in the plasma and
HTLV-1 PVL in infected individuals (i.e., chronic HAM/
TSP patients and ACs) (Spearman’s rank correlation coef-
ficient n=29, r=0.031, P=0.873; Figure 3B). We then tested
disease specificity by measuring the levels of sOX40 in the
CSF from both rapidly progressive and chronic HAM/
TSP patients, and in patients with other neurological dis-
orders, with and without inflammation (e.g., 12 MS, 8
aseptic meningitis, 5 systemic lupus erythematosus with
neurological manifestations, 9 chronic inflammatory de-
myelinating polyneuropathy, 6 Guillain-Barré syndrome,
and 9 amyotrophic lateral sclerosis patients). As shown in
Figure 3C, CSF sOX40 levels were markedly increased in
patients with rapidly progressive HAM/TSP (n=3) and
aseptic meningitis (n=8). The CSF sOX40 levels in other
HTLV-1-infected inflammatory neurological diseases, i.e.
any inflammatory neurological disorders except for HAM/
TSP that occurred in HTLV-1 infected individuals,
(HTLV-1+ OINDs, n=6) was not significantly different
from chronic HAM/TSP (n=20), whereas the sOX40
level of HTLV-1+ OINDs was significantly increased
compared to non-infected OINDs (HTLV-1- OINDs,
n=26; Figure 3D).
Of the HAM/TSP patients studied, paired CSF and
plasma samples, i.e., blood and CSF were collected on
the same day, were available for six patients. HAM/TSP
patients No.10-12 had a lower concentration of sOX40
in the CSF than in the plasma (Table 2), and the patients
showed a typical clinical course of HAM/TSP (i.e. slowly
progressive symmetrical myelopathy) and had no history
of rapid exacerbation. In contrast, HAM/TSP patients
No.13-15, who had higher concentrations of sOX40 inthe CSF than in the plasma, showed a rapidly progres-
sive clinical course (i.e. patients became unable to walk
within three months after onset of initial symptoms).
Expression of OX40 in inflammatory mononuclear cells in
spinal cord lesions of HAM/TSP patient with short disease
duration and progressive symptoms
We also examined autopsy specimens from HAM/TSP
patients by immunohistochemical staining. Although
there was reduced or no OX40 protein expression in
HAM/TSP patients who had a long duration of illness
and who no longer had active inflammation (a represen-
tative example is shown in Figure 4A), we observed
marked OX40 expression in inflammatory round-shaped
mononuclear cells around the blood vessels in spinal
cord lesions from one HAM/TSP patient (Figure 4B).
This patient (patient 1 in refs [35-38], who had a shorter
disease duration of up to 2.5 years after the onset of neuro-
logical symptoms) showed predominant infiltration of CD4+
T cells [36] that also expressed tax mRNA [38], pro-
inflammatory cytokines [37], and matrix metalloproteinases
[39]. In contrast, we observed only low background staining
for OX40L in spinal cord tissues of all the HAM/TSP
patients examined (a representative example is shown
in Figure 4C) compared to positive control (Figure 4D).
Anti-OX40 monoclonal antibody specifically eliminated
naturally infected CD4+ T cells via antibody-dependent
cell-mediated cytotoxicity (ADCC) in cultured PBMCs
We investigated the role of OX40 in HTLV-1 naturally
infected CD4+ T cells, by testing the effects of an anti-
human OX40 mAb on Tax expression. As shown in Figure 5,
anti-OX40 mAb (clone B-7B5) reduced the percentage of
Tax-positive cells, whereas the isotype control mAb (clone
2C2: anti-HIV-1 gp21, mouse IgG1) had no effect on Tax
expression (Figure 5, 1st, 2nd, and 3rd panels from left).
Culture of PBMCs with anti-CD16/CD32 (Fc receptor) anti-
body to block Fc receptors abolished Tax suppression by
anti-OX40 mAb (Figure 5, 4th panels from left), suggesting
that the effect of the anti-OX40 mAb (B-7B5) is mainly
mediated by ADCC. We further tested the effects of the
F(ab’)2 fragment of anti-OX40 mAb (B-7B5) and found
that the F(ab’)2 fragment did not suppress Tax expres-
sion; this finding supports an ADCC mechanism of ac-
tion of the anti-OX40 mAb (Figure 5, right panels).
Anti-OX40 monoclonal antibody specifically eliminated
OX40-positive HTLV-1 infected cells in cultured PBMCs
We examined whether suppression of OX40 expression
either reduced the frequency of Tax-positive cells or se-
lectively eliminated HTLV-1-infected cells by isolating
CD4+ T cells from PBMCs before and after culture,
extracting genomic DNA, and measuring HTLV-1 PVL.
HTLV-1 PVL in CD4+ T cells was significantly reduced
Table 1 The expression of pro-inflammatory cytokines in peripheral blood mononuclear cells of HTLV-1 infected individuals
Case Age Sex PVLa %IFN-γ+ in %IFN-γ+ in %IFN-γ+ in %IFN-γ+ in % TNF-α+ in % TNF-α+ in % TNF-α+ in % TNF-α+ in
CD4+OX40+b CD4+OX40- CD4+Tax+c CD4+Tax- CD4+OX40+ CD4+OX40- CD4+Tax+ CD4+Tax-
HAM/TSP7 68 F 1200 56.3 8.9 74.1 12.4 66.9 26.1 70.8 25.3
HAM/TSP8 68 F 1118 77.2 5.0 91.5 4.7 84.1 10.0 87.6 10.7
HAM/TSP9 71 F 1424 64.8 4.7 80.1 5.3 70.4 18.8 80.5 16.6
mean±SE 69.0±1.0 1247±65 66.1±4.3 6.2±1.0 81.9±3.6 7.5±1.7 73.8±3.7 18.3±3.3 79.6±3.4 17.5±3.0
AC4 74 F 435 61.9 13.8 61.8 13.6 30.8 11.5 25.0 11.1
AC5 76 M 139 55.3 24.9 43.0 27.8 38.3 22.1 47.9 14.3
AC6 71 F 250 47.3 15.0 62.1 34.6 15.8 10.5 34.8 21.9
mean±SE 73.7±1.5 275±61 54.8±3.0 17.9±2.5 55.6±4.5 25.3±4.4 28.3±4.7 14.7±2.6 35.9±4.7 15.8±2.3
HAM/TSP: HTLV-1 associated myelopathy/tropical spastic paraparesis. AC: asymptomatic carrier. PVL: Proviral load.
a PVL: HTLV-1 tax copy number per 104 peripheral blood mononuclear cells (PBMCs).
b “%IFN-γ+ in CD4+OX40+” means the frequency of IFN-γ+ cells in the CD4+OX40+ cell gate.














Table 2 Clinical and laboratory findings of HAM/TSP patients for whom paired CSF and plasma samples were tested
for soluble OX40 (sOX40)
Case Age Sex Disease HTLV-1 proviral load HTLV-1 OMDS* sOX40 sOX40
Duration (copies/104PBMCs) Ab titer (PA) (Plasma) (CSF)
HAM/TSP10 67 F 6 years 698 ×4096 7 534.9 52.1
HAM/TSP11 29 F 1 year 1138 ×16384 2 394.0 54.1
HAM/TSP12 41 F 5 years 800 ×16384 4 1459.0 55.6
HAM/TSP13 62 F 1 month 224 ×8192 10 626.6 752.1
HAM/TSP14 75 F 3 months 437 ×4096 9 337.6 897.4
HAM/TSP15 66 F 2 months 534 ×4096 9 423.5 652.5
*OMDS: Osame Motor Disability Score that graded the motor dysfunction from zero (normal walking and running) to 13 (complete bedridden): 1=normal gait but
runs slow; 2=abnormal gait; 3=abnormal gait and unable to run; 4=need support while using stairs; 5=need one hand support in walking; 6=need two hands
support in walking; 7=need two hands support in walking but is limited to 10 m; 8=need two hands support in walking but is limited to 5 m; 9=unable to walk but able
to crawl on hands and knees; 10=crawls with hands; 11=unable to crawl but can turn sideways in bed; 12=unable to turn sideways but can move the toes.
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did not suppress expression of Tax but specifically elimi-
nated OX40-positive HTLV-1 infected cells (Figure 6).
Discussion
Retroviral infection is characterized by chronic immune-
system activation and pro-inflammatory cytokine pro-
duction [40]. HTLV-1 infection is associated with theA
C
Figure 4 Expression of OX40 in inflammatory mononuclear cells in sp
and progressive symptoms. We studied autopsy specimens from 9 HAM
cells are detected in the spinal cord lesion without active inflammation of
B. Many infiltrating mononuclear cells are positively stained by anti-OX40 m
patient with 2.5 years of illness. Magnification: ×40. C. There was reduced o
patients. OX40L showed only low background staining and there was no O
spinal cord lesions. Magnification: ×20. D. Positive control staining for OX40development of several different inflammatory conditions,
including chronic arthritis, pulmonary alveolitis, polymyo-
sitis, Sjögren syndrome, and uveitis [41]. The main patho-
logical feature of HAM/TSP is chronic inflammation of
the spinal cord, characterized by perivascular cuffing of
mononuclear cells accompanied by parenchymal lympho-
cytic infiltration. Increased spontaneous peripheral blood
lymphocyte proliferation with the production of TNF-αB
D
inal cord lesions of HAM/TSP patient with short disease duration
/TSP patients by immunohistochemical staining. A. No OX40 positive
a HAM/TSP patient with a long duration of illness. Magnification: ×40.
Ab in the spinal cord lesion with active inflammation of HAM/TSP
r no OX40L protein expression in spinal cord tissues of HAM/TSP
X40L positive staining on inflammatory mononuclear cells in the











































Figure 6 The HTLV-1 proviral load in CD4+ T cells were
significantly reduced after cultivation. CD4+ T cells were isolated
from PBMCs before and after cultivation, extracted genomic DNA,
and measured the HTLV-1 PVL. HTLV-1 PVL in CD4+ T cells was
significantly reduced after culture.
Figure 5 Anti-OX40 monoclonal antibody specifically eliminated naturally infected CD4+ T cells via antibody-dependent cell-mediated
cytotoxicity (ADCC) in cultured PBMCs. Anti-OX40 mAb (clone B-7B5) reduces the percentage of Tax-positive cells, whereas the isotype control
mAb (clone 2C2: anti-HIV-1 gp21, mouse IgG1) has no effect on Tax expression (1st, 2nd, and 3rd panels from left). Culture of PBMCs with
anti-CD16/CD32 (Fc receptor) antibody to block Fc receptors abolishes Tax suppression by anti-OX40 mAb (4th panels from left). F(ab’)2 fragment
do not suppress Tax exppression (right panels).
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hypergammaglobulinemia, and complement fixing immune
complexes have also been reported in HAM/TSP patients
[6]. Recent research has shown the importance of OX40-
OX40L interactions in the development of immune-
mediated diseases. Specifically, a strong reduction in disease
severity, or a complete lack of disease, has been reported
when OX40 or OX40L is absent or neutralized in animal
models. We therefore hypothesized that the OX40-positive
subpopulations of chronically activated T cells exist in nat-
urally HTLV-1-infected cells of HAM/TSP patients. These
cells may function to accelerate inflammation, and blocking
OX40 may have therapeutic potential in the treatment of
HAM/TSP.
Previous reports indicated that OX40 is strongly stimu-
lated by the HTLV-1 viral transactivator Tax [15,19,20].
However, these previous findings were obtained by north-
ern blot or western blot analysis using whole cells. Thus, it
was not clear if this induction occurs in naturally infected
CD4+ T cells of HTLV-1 infected individuals. In the
present study, our flow cytometry analysis clearly showed
that almost all OX40-positive cells are Tax-positive after
short-term culture of naturally HTLV-1-infected cells,
suggesting that OX40 is driven exclusively by Tax at the
single cell level. In contrast, flow cytometry analysis of
JPX-9 cells showed higher percentages of OX40+Tax- cells,
as well as OX40+Tax+ cells, after induction of Tax.
Although the reasons for this discrepancy are not clear, it
can be caused by differential modulation of surface andintracellular protein expression in JPX-9 cells. Our ELISA
analysis indicates the existence of intracellular pools of
OX40, suggesting that Tax+OX40- cells also contain Tax-
induced OX40 within JPX-9 cells. While the expression of
another co-stimulatory member of the TNFR family, 4-
1BB, has also been reported [32], our data indicate that the
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of 4-1BB in Tax+CD4+ T cells naturally infected with
HTLV-1. It has been previously reported that Tax strongly
activates the 4-1BB promoter via a single NF-κB site [32]
and the OX40 promoter via 2 NF-κB sites [16]; hence,
sustained activation of NF-κB leads to increased expression
of numerous pro-inflammatory cytokines and growth factors
[44] via NF-κB signaling pathways and ultimately leads to
chronic inflammation. In support of these observations, our
results show that the frequencies of pro-inflammatory cyto-
kine positive cells within the OX40+CD4+ and Tax+CD4+
populations from HAM/TSP patients are significantly
higher than OX40-CD4+ and Tax-CD4+ T cells, respectively.
These cells may be more likely to cross the blood brain
barrier and enter the CNS, attract other cells including pro-
inflammatory virus-specific CD8+ cells, and result in by-
stander damage to the CNS tissue.
The experimental autoimmune encephalomyelitis (EAE)
rat model of human MS shows a selective upregulation of
the OX40 protein in encephalitogenic myelin basic
protein-specific T cells in the spinal cord during onset of
the disease [21]. In contrast, T cells isolated from periph-
eral blood and spleen of the same animal express low
levels of OX40 [21]. This is similar to our present finding,
where OX40 was markedly expressed in infiltrating mono-
nuclear cells in spinal cord lesions, but not in uncultivated
PBMCs from HAM/TSP patients. Because locally pro-
duced pro-inflammatory cytokines up-regulate MHC class
II molecules on astrocytes and microglia, increase presen-
tation of CNS antigens, and exert a direct cytotoxic effect
on oligodendrocytes [45], the observed expression of
OX40 in inflammatory mononuclear cells in spinal cord
lesions suggest a role for OX40 in inflammation and neur-
onal damage that occurs in the CNS of HAM/TSP
patients. In the rat EAE model, selective depletion of
myelin-reactive T cells, by treatment with an anti-OX40
mAb-conjugated immunotoxin, effectively suppressed
disease symptoms [21]. The association of clinical pro-
gression of HAM/TSP with increased HTLV-1 PVL in
individual patients [9] and the strong stimulation of
OX40, together with the expression of the viral
transactivator Tax in CD4+ T cells, indicates that targeting
of OX40 positive T cells by anti-OX40 antibodies may
provide a novel therapeutic strategy for the treatment of
HAM/TSP.
In the present study, an anti-OX40 monoclonal anti-
body specifically eliminated naturally infected CD4+
T cells in cultured PBMCs via ADCC. This indicates that
effector cells may actively lyse HTLV-1-infected CD4+ T
cells that are bound by the anti-OX40 antibody. Indeed,
defucosylated humanized anti-CC chemokine receptor 4
(CCR4) mAbs, which exert a strong ADCC effect, were
found to be effective and well tolerated as a treatment for
patients with relapsed CCR4-positive ATL or peripheralT-cell lymphoma [46]. In the present study, OX40 expres-
sion was not observed in T cells of healthy individuals,
and its expression was more specific than CCR4 for
HTLV-1-infected cells. This finding suggests that specific
elimination of HTLV-1-infected T cells by defucosylated
humanized anti-OX40 monoclonal antibodies might be a
promising future approach for treatment of HAM/TSP.
We also found that plasma sOX40 levels were more
elevated in HTLV-1-infected individuals (chronic HAM/
TSP patients and ACs) than in NCs. Three rapidly pro-
gressive HAM/TSP patients also showed higher levels of
sOX40 in the CSF than in the plasma, suggesting the
possibility that sOX40 is released at high levels following
strong intrathecal immune activation. In contrast,
expression of OX40L was absent in HTLV-1-infected
lymphocytes even after short term ex vivo cultivation, in
active-chronic spinal cord lesions of HAM/TSP patient,
and in plasma of HTLV-1 infected individuals. There-
fore, OX40 signals might be generated by interactions
with OX40L on antigen presenting cells or endothelial
cells at specialized sites such as lymphoid organs. In
such lesions, similar to other members of the TNF
receptor superfamily like 4-1BB, sOX40 may act as an
antagonist to membrane-bound receptors and induce
signaling in OX40L+ cells to produce cytokines, which
in turn drive specific T helper (Th)-cell differentiation
and suppress the generation of adaptive Tregs to partici-
pate in HAM/TSP pathogenesis.
In conclusion, we demonstrate that OX40 was specific-
ally expressed in CD4+ T cells naturally infected with
HTLV-1. These cells have the potential to produce pro-
inflammatory cytokines along with the expression of the
viral transactivator Tax. Higher levels of sOX40 were found
in the CSF than in the plasma of three rapidly progressive
HAM/TSP patients, and OX40 was overexpressed in the
spinal cord infiltrating mononuclear cells of HAM/TSP
patient with active disease. Anti-OX40 mAb was able to
specifically eliminate HTLV-1-infected CD4+OX40+Tax+
T cells via ADCC. These findings indicate that, in addition
to its established role in the regulation of T cell division
and survival, OX40 may be a key molecule in the patho-




Peripheral blood was studied from 23 patients with a
clinical diagnosis of HAM/TSP, 9 ACs and 13 uninfected
normal controls (NCs). The diagnosis of HAM/TSP was
made according to the World Health Organization diag-
nostic criteria [47]. In this paper, chronic HAM/TSP
means typical cases fulfilling diagnostic criteria and
rapidly progressive HAM/TSP is defined by patients’ in-
capacity to walk unaided within three months after
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http://www.retrovirology.com/content/10/1/51symptoms’ onset. This study was approved by the Insti-
tutional Review Board of the University of the Ryukyus
with license number H21-1-9. All patients provided writ-
ten informed consent for the collection of samples and
subsequent analysis. The CSF and plasma samples were
collected before starting therapy. Control subjects of
other neurological diseases were MS (n=12), aseptic
meningitis (n=8), systemic lupus erythematosus (SLE)
with neurological manifestations (n=5), chronic inflam-
matory demyelinating polyneuropathy (CIDP) (n=9),
Guillain-Barré syndrome (GBS) (n=6), and amyotrophic
lateral sclerosis (ALS) (n=9). The specimens were stored
at −80°C until use.
Cell culture
Six HTLV-1 infected T-cell lines (HUT-102, MT-1, MT-2,
MT-4, SLB-1, C5/MJ) and two HTLV-1-uninfected T-cell
lines (CEM-OX40L, CEM-OX40) were used in this study.
CEM-OX40 and CEM-OX40L cell lines are stable CEM-
derived cell lines expressing the human OX40 or OX40L,
respectively. The Tax-inducible JPX-9 cell line is a deriva-
tive of the Jurkat HTLV-1 negative human T cell leukemia
cell line, which expresses biologically active Tax protein
under the control of the metallothionein promoter [29].
These cells were cultured in RPMI 1640 medium
supplemented with 10% heat inactivated fetal calf serum
(FCS), 50 U/ml penicillin, and 50 μg/ml streptomycin
(Wako) at 37°C in 5% CO2.
Preparation of PBMC samples
Fresh peripheral blood mononuclear cells (PBMCs) were
isolated on a Histopaque-1077 (Sigma) density gradient
centrifugation, washed twice in RPMI 1640 with 10%
heat inactivated FCS, and stored in liquid nitrogen as
stocked lymphocytes until use. CD4+ T cells were iso-
lated from PBMCs by positive immunoselection with the
Dynal® CD4-positive isolation kit (Invitrogen), according
to the manufacturer’s protocol. In brief, PBMCs were in-
cubated with anti-CD4-coated beads for 30 min at 4°C
under gentle tilt rotation. Captured CD4+ cells were col-
lected with a magnet (Dynal MPC-S) and detached from
beads with DETACHaBEAD CD4/CD8® (Invitrogen).
Purity was >99% CD4+ T cells, as determined by flow
cytometry (data not shown). To induce cytokine produc-
tion by OX40+CD4+ T cells, PBMCs were cultivated for
12 hours, then 0.1 ng/ml phorbol myristate acetate
(PMA) (Sigma) and 0.5 μg/ml A23187 (Sigma) and 2
mM monensin (Sigma) were added to the culture
medium and further cultivated for 5 hours.
Monoclonal antibodies and reagents
We produced the following monoclonal antibodies (mAbs)
in our laboratory: mouse IgG1 mAbs anti-human OX40L
(clones 5A8, 8F4), anti-human OX40 (clones B-7B5 and17D8), anti-HIV-1 p24 (clone 2C2 and NP24), and mouse
IgG3 mAb anti-HTLV-1 Tax (clone Lt-4) [48] as well as rat
IgG2b mAbs anti-human OX40 (clone W4-54), anti-
human OX40L (clone W18) and isotype control anti-HCV
(clone MO-8). Some of these mAbs were labeled using
FITC, Cy5, or HRP using commercial labeling kits (Dojin
or Amersham, Japan) according to the manufacturers’
instructions. Biotinylated recombinant soluble human
OX40L (sOX40L in a form of murine CD8-fusion protein)
was purchased from Ancell (Bayport, MN) and used with
PE-streptavidin (Biolegend) for staining. Recombinant hu-
man OX40 ligand/TNFSF4 and recombinant human
OX40/TNFRSF4/Fc Chimera were purchased from R&D
Systems (Minneapolis, MN) and used for the standard
curve in sOX40L and sOX40 ELISA, respectively.
Immunohistochemistry
Immunohistochemical staining of the spinal cord speci-
mens from HAM/TSP patients was performed on buff-
ered formalin-fixed paraffin-embedded sections using
EnVision (DAKO) method for signal detection as de-
scribed previously [36]. The clinical and pathological
characteristics of the patients are described elsewhere
[36-39]. The monoclonal antibodies to OX40 (clone B-
7B5) and OX40L (clone 8F4) were used at a final con-
centration of 1 μg/ml.
Flow cytometry
Cell surface staining
After thawing, cells were washed three times with
phosphate-buffered saline (PBS) and fixed in PBS
containing 2% paraformaldehyde (Sigma) for 20 minutes
at 4°C. Fixed cells were washed with PBS containing 7% of
normal goat serum (Sigma) and then incubated for 15 mi-
nutes at room temperature with various combinations of
fluorescence-conjugated mAbs as follows: phycoerythrin-
cyanin 5.1 (PC5)-labeled anti-CD4 (13B8.2), PC5-labeled
anti-CD8 (B9.11), phycoerythrin (PE)-labeled anti-CD4
(13B8.2) (Beckman Coulter), PE-labeled anti-4-1BB (4B4)
(eBioscience), fluorescein isothiocyanate (FITC)-labeled
anti-OX40 (B-7B5) and OX40L (5A8). Isotype matched
mouse immunoglobulins were used as a control. After the
staining procedure, the cells were washed twice and ana-
lyzed by standard flow cytometry using a FACS Calibur
and Cell Quest software (BD).
Concomitant detection of intracellular and cell surface
molecules
For intracellular staining of Tax and/or cytokines, surface
stained cells were washed and permeabilized with PBS/7%
normal goat serum containing 0.2% saponin (Sigma) (PBS-
SAPO) for 10 minutes at room temperature. Permeabilized
cells were then washed twice and resuspended in PBS-
SAPO containing FITC or cyanin 5 (Cy5)-labeled anti-Tax
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PE-labeled IFN-γ (BD Pharmingen) mAb for 20 minutes at
room temperature. Finally, the cells were washed twice and
analyzed by flow cytometry.Flow cytometry based binding assay
To determine whether cell surface OX40 is functional,
aliquots of Fc-blocked cells were incubated with
biotinylated recombinant soluble OX40L at a concentra-
tion of 2.5 mg/ml for 30 min on ice, followed by staining
with PE-streptavidin (Biolegend) for 30 min on ice. After
the staining procedure, the cells were washed twice and
analyzed by flow cytometry.ELISA
Cell lysates were prepared by lysis of 2 × 107 cells in 1ml
of a lysis buffer (10 mM Tris–HCl, pH8.0, 140 mM
NaCl, 3 mM MgCls, 2 mM phenylmethylsulfonyl fluor-
ide, 0.5% Nonidet P-40) on ice for 20 min, followed by
centrifugation at 13,000 × g for 10 min at 4°C. Both
OX40 and OX40L levels in cell lysates, culture superna-
tants, plasma and CSF were assayed by in house made
sandwich ELISA using monoclonal antibodies against
OX40 (clone 17D8 for capture and W4-54 for detection)
and OX40L (clone 8F4 for capture and W18 for detec-
tion). Briefly, 96-well Immuno Module/Strip Plates
(Nunc) was coated with either anti-OX40 monoclobal
antibody (clone 17D8) or anti-OX40L monoclobal anti-
body (clone 8F4) at 4°C overnight, then blocked with 1%
casein in 0.02% thimerosal-PBS at room temperature for
30 min. After washing plates three times with wash buf-
fer (PBS with 0.05% Tween 20, pH 7.5), 50 μl of irrele-
vant mouse IgG1 (anti-HIV1 p24 mAb NP24) was added
into each well as a blocking antibody. OX40 or OX40L
standard was diluted to 4,000 pg/ml in dilution buffer
(PBS with 0.1% BSA, 0.5% Triton X100, 0.05%
Tween20), and two-fold serial dilutions were performed
ranged from 4,000 to 16 pg/ml. Then 50 μl of the diluted
standard or samples (cell lysates, culture supernatants,
plasma and CSF) were added into 96-well plates and in-
cubated one hour at room temparature. After washing
plates three times, 50 μl each of diluted (0.2 μg/μl) anti-
OX40 monoclobal antibody (clone W4-54) or anti-
OX40L monoclobal antibody (clone W18) conjugated to
HRP was added as detection antibody and incubated for
one hour at room temperature. Color reactions using
alkaline-phosphatase substrate (Sigma-Aldrich) were
then evaluated by Model 680 Microplate Reader (Bio-
Rad) reading at 450 nm with reference at 630 nm, and
the data was analyzed using the Microplate manager III
software (Bio-Rad). Results are shown as mean ± SE for
duplicate wells. Human interleukin-2 soluble receptor
alpha (IL-2sRα) was measured by ELISA according tothe manufacturer’s instruction (Quantikine Human IL-
2sRα Immunoassay, R&D Systems, Inc. MN).
Genomic DNA, RNA extraction and cDNA synthesis
Genomic DNA was extracted from the frozen PBMCs by
QIAamp blood kit (QIAGEN, Tokyo, Japan). RNA from
1×105 enriched CD4+ T cells was extracted using RNeasy
Mini Kit with on-column DNase digestion (QIAGEN,
Tokyo, Japan) according to the manufacturer’s instruc-
tions. Complementary DNA (cDNA) was synthesized
using PrimeScript® RT reagent Kit (Takara, Kyoto, Japan).
All reaction procedures were performed as suggested by
the manufacturer.
Quantification of HTLV-1 proviral load and anti-HTLV-1
antibody titers
To examine the HTLV-1 PVL, we carried out a quantita-
tive PCR method using Thermal Cycler Dice® Real Time
System (Takara, Japan) with 100 ng of genomic DNA
(roughly equivalent to 104 cells) from PBMCs samples as
reported previously [8]. Based on the standard curve cre-
ated by four known concentrations of template, the con-
centration of unknown samples were determined. Using
β-actin as an internal control, the amount of HTLV-1 pro-
viral DNA was calculated by the following formula: copy
number of HTLV-1 tax per 1 × 104PBMCs = [(copy num-
ber of tax)/(copy number of β − actin/2)] × 104. All samples
were performed in triplicate. Serum HTLV-1 antibody
titers were determined by a particle agglutination method
(Serodia-HTLV-1®, Fujirebio, Japan).
Real-Time RT-PCR analysis
We used the real-time RT-PCR method to carry out a quan-
titative analysis of the expression of the tax and OX40
mRNA by using Thermal Cycler Dice® Real Time System
(Takara, Japan) as reported previously [49]. HTLV-1 tax or
OX40 mRNA load was calculated by the following formula:
HTLV- 1 taxmRNAload = valueof tax/valueofHPRT(Hypo-
xanthine Phosphorisbosytransferase). OX40 mRNA load =
value of OX40/value of HPRT. We used aliquots of the same
standard MT-2 cDNA preparation for all assays and the
correlation values of standard curves were always more than
99%. The sequences of primers for tax mRNA detection
were as follows: 5′- ATC CCG TGG AGA CTC CTC AA-3′
and 5′- ATC CCG TGG AGA CTC CTC AA-3′, and the
probe that surrounded the splice junction site of tax mRNA
was 5′- TCC AAC ACC ATG GCC CAC TTC CC-3′. The
sequences of primers for OX40 mRNA detection were as fol-
lows: 5′-AAC CAG GCC TGC AAG CCC T-3′ and 5′-
GTC CCT GTC CTC ACA GAT T-3′, and the probe that
span the junction between exon 4 and 5 was 5′- ACC AAC
TGC ACC TTG GCT GGG AAG CA-3′. We used the
HPRT primers and probe set (Applied Biosystems) for in-
ternal calibration. All assays were performed in triplicate.
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To test for significant differences among the cell popula-
tions between three different groups of subjects (HAM/
TSP, ACs and NCs), the Kruskal-Wallis test was employed.
For multiple comparisons, we used Sheffe’s F to analyze
statistical difference. Correlations between variables were
examined by Spearman rank correlation analysis. We made
paired comparison of changes in HTLV-1 PVL in CD4+
T cells before and after PBMCs cultivation by using a
paired t-test. The results represent the mean ± SE
where applicable. Values of p<0.05 were considered sta-
tistically significant.Additional files
Additional file 1: Figure S1. OX40 was expressed on the surface of Tax+
CD4+ T cells from HTLV-1 infected individuals. OX40 was detected on CD4+
T cells of HAM/TSP patients (HAM/TSP3, 4) and AC (AC1) with anti-OX40
mAb (clones B-7B5) after 16 hours in vitro cultivation in the absence of any
growth factors or mitogen (center panels). OX40 was expressed almost
exclusively in naturally infected CD4+ T cells that also expressed Tax (right
panels). FigureS2. The expression of 4-1BB on CD4+ T cells from HAM/TSP
patients. A. 4-1BB was detected on both CD4+ and CD4- T cells of HAM/TSP
patients with anti-4-1BB mAb (clone 4B4, eBioscience) after 16 hours in vitro
cultivation in the absence of any growth factors or mitogen. B. Tax protein
was detected in CD4+ T cells after 16 hours in vitro cultivation. C. The
expression of 4-1BB was associated with the expression of Tax. Figure S3.
Functional OX40 is specifically expressed on the surface of T cells naturally
infected with HTLV-1. To determine if cell surface OX40 is functional, flow
cytometry based binding assays have been carried out. Aliquots of Fc-
blocked cells were incubated with biotinylated recombinant soluble OX40L
at a concentration of 2.5 mg/ml for 30 min on ice. Then cells were washed
and stained with PE-streptavidin (Biolegend) and PC5-labeled anti-CD4 for
30 min on ice. After washing, the cells were fixed and processed to detect
concomitantly Tax (see Methods). The frequency of CD4+ T cells that were
positively stained with biotinylated recombinant soluble OX40L and PE-
streptavidin was similar to the percentage of CD4+ T cells stained by anti-
OX40 mAb, indicating that these cells expressed functional OX40.
Additional file 2: Table S1. Ex vivo frequency of OX40 and Tax positive
T cells in peripheral blood mononuclear cells from HTLV-1 infected
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